The pharma twitter study series is Whydot’s research study and syndicated advisory service benchmarking how pharma companies engage via twitter. It is the most extensive study undertaken to date: a benchmark of 15 pharma twitter accounts and their over 50,000 followers! All accounts benchmarked were Global corporate communication accounts, except for AstraZeneca, Boehringer Ingelheim and GSK, where also US accounts were included. Pharma Twittersphere. The study objectives are to analyze who follows pharma twitter accounts: segmenting followers by stakeholder, activity and therapeutic area interest.